Clinical Trial Update: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma [Phase 2]

View source ↗

Summary

Phase 2 safety study evaluating dinutuximab combined with immunotherapy for neuroblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• dinutuximab (dinutuximab)

Snippet

Sponsor: Fundació Sant Joan de Déu | Conditions: Neuroblastoma, Neoplasm, Residual | Phase 2 | Status: COMPLETED